These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1053888)

  • 1. Chairman's Introductory remarks.
    Shulman NR
    Ann N Y Acad Sci; 1975 Jan; 240():7. PubMed ID: 1053888
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in hemophilia. Part II. Genetics. Chairman's introductory remarks: Detection of the carrier state of classic hemophilia.
    Ratnoff OD; Steinberg AG
    Ann N Y Acad Sci; 1975 Jan; 240():95-6. PubMed ID: 1078624
    [No Abstract]   [Full Text] [Related]  

  • 3. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 4. Modern treatment of hemophilia: from the shadows towards the light.
    Mannucci PM
    Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
    [No Abstract]   [Full Text] [Related]  

  • 5. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 9. Visualization of VIII:C-like material in a CRM negative hemophiliac.
    Rock GA; Palmer DS; Cruickshank WH
    Thromb Res; 1979; 16(5-6):747-57. PubMed ID: 524319
    [No Abstract]   [Full Text] [Related]  

  • 10. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 11. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 12. [The current therapeutic bases for hemophilia].
    Négrier C
    Transfus Clin Biol; 2000 Jun; 7(3):257-8. PubMed ID: 10919215
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
    Kamiya T
    Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
    [No Abstract]   [Full Text] [Related]  

  • 15. Factor VIII (AHF) activity of small size produced by succinylating plasma.
    Barrow EM; Graham JB
    Am J Physiol; 1972 Jan; 222(1):134-41. PubMed ID: 4536749
    [No Abstract]   [Full Text] [Related]  

  • 16. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in hemophilia. Part III. Discussion paper: The Red Cross program.
    Greenwalt TJ
    Ann N Y Acad Sci; 1975 Jan; 240():208-12. PubMed ID: 1053865
    [No Abstract]   [Full Text] [Related]  

  • 18. Whole blood collection using metered anticoagulation for production of Factor VIII and Factor IX.
    Penny A; Pinner M; Townley A; Mosley P; Smith J; Lane R; Munford C; Robinson A
    Prog Clin Biol Res; 1990; 337():487-9. PubMed ID: 2112756
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent advances in hemophilia. Part III. Our lipid tissue. Chairman's introductory remarks.
    Swisher SN
    Ann N Y Acad Sci; 1975 Jan; 240():154. PubMed ID: 1053860
    [No Abstract]   [Full Text] [Related]  

  • 20. [Virus in hemophilia: current status and future perspectives].
    Aguilar C; Félix Lucía J
    Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.